The Compound That Cured My Brain Fog in 30 Days: My Microdose Ibogaine Experiment Under Guru Ameen

Why I’m Writing This Now

Late last year the Department of Justice indicted my friend Ameen Alai — known across the hardcore fitness world as Guru Ameen, or “The Mad Scientist” — on a count of distribution resulting in death. The charge carries a mandatory minimum of 20 years. The substance: ibogaine, a naturally occurring alkaloid from the root bark of the West African shrub Tabernanthe iboga.

If you’ve spent time in the bodybuilding world in the last two decades you know who Ameen is. If you haven’t, here’s the short version: he’s one of the most brilliant underground biochemistry minds in the hardcore fitness space, a father, a coach, and for the last several years the single loudest public voice in the United States on ibogaine as a tool for interrupting addiction. I’ve known Ameen for six years, since 2017, and I’ve spent enough time with him to know that the federal government has the wrong target.

This article is the first in what I expect to be a long series. Not because I want to write about legal battles — I’d rather write about training, hormones, peptides, and the compounds I’ve built my whole brand around — but because the molecule the feds are prosecuting Ameen over is one of the most consequential pieces of neurochemistry humanity has ever stumbled onto. the science is no longer debatable. The politics just haven’t caught up. And I can’t watch a friend get buried for being early.

I’m also writing it because, frankly, I owe Ameen. He’s the man who walked me, carefully, through my first microdose ibogaine protocol — and I’ve been running that protocol for the better part of a year. What I’ve learned should be on the record.

The 30-Day Microdose Experiment — Under Guru Ameen’s Supervision

Let me be completely direct. Over the last year I have been microdosing ibogaine under Ameen’s direct supervision. EKG first. QTc screen first. Baseline bloodwork first. Titrated dose. Structured intervals. Log everything.

That last part matters because ibogaine is not something you play with. It is a hard-reboot tool. At the flood dose — 10 to 20 mg per kilogram of bodyweight — it produces a 12-hour oneirogenic state, a kind of waking dream that forces the user to confront whatever trauma originally built their addiction pattern. Done wrong, it is dangerous. Done right, it is arguably the single most effective anti-addiction intervention known to medicine.

Microdose is different. We’re talking 2 to 8 mg of ibogaine HCl at a time, orders of magnitude below the visionary threshold. You do not feel the characteristic oneirogenic wave. What you feel — over weeks — is a slow, profound recalibration. Less compulsive mental chatter. Cleaner mornings. The cravings that steer all of us, addict and non-addict alike, simply quieter. A feeling I’ve come to describe as settled.

Ameen insisted on several guardrails from day one:

• Cardiac screening is non-negotiable. Ibogaine blocks the hERG potassium channel and prolongs the QT interval. You need an EKG before your first dose, and periodic re-checks. This is not optional.
• Never stack with SSRIs, SNRIs, methadone, tramadol, or any QT-prolonging medication. Period.
• Know your liver. CYP2D6 metabolism matters. Some people are rapid metabolizers, some are slow. Guru built a personalized dose based on how I responded to tracer doses.
• Log symptoms daily. Sleep, HRV, mood, cravings, resting heart rate. Patterns emerge faster than you’d think.

After 30 days I had noticeable improvements in focus, mood baseline, and (most surprisingly to me) my food relationship. After six months I had durable behavior changes I couldn’t replicate with any other stack I’ve run in 20 years of experimentation. By one year I had a personal library of neurochemical insight I will be drawing on for the rest of my life.

Why Ameen, and Not a Doctor

This is the part that will be uncomfortable for the medical establishment reading this, so let me say it plainly: when I move up to a full flood dose — and I will, once the risk profile and my cardiac baseline are where Ameen says they need to be — it will be under Ameen’s supervision. Not a hospital. Not a licensed psychiatrist. Not a doctor with a diploma on the wall who has never once personally experienced the molecule they’re offering to administer.

I trust Ameen because Ameen has lived this. He has taken ibogaine himself — in Mexico, where it’s legally available — multiple times. He used it to liberate himself from a personal dependency battle he’s been publicly honest about for years. He has supervised more sessions, more safely, than any MD in the United States. He reads every paper. He knows the pharmacokinetics better than most pharmacologists. And he has the one thing medical professionals structurally cannot offer: the protocol knowledge that only comes from having gone through the experience yourself.

There is a pattern in medicine I want to name. Ask a doctor how to fix your testosterone and they reach for the trt protocol their CME training gave them — which is fine if you want to be in their office once a month for the rest of your life, but which will never match the protocol knowledge of a man who has spent decades optimizing his own HPG axis and helping thousands of others do the same. Ask a doctor how to reverse addiction and they will offer you Suboxone, methadone, or a rehab program with a 70% relapse rate. Ask Ameen and he will walk you through a neurochemical reset that, in one session, does what a decade of conventional treatment cannot.

The people who know this medicine best are the people the medical establishment doesn’t credential, because credentialing them would force the system to admit it has been systematically failing addicts for 40 years.

The tony huge Laws of Biochemistry Physics — Law 1 Applied

The tony huge laws of Biochemistry Physics start with Law 1: Governors vs Accelerators. Every biological system has governors (negative feedback loops — myostatin limiting muscle growth, aromatase converting testosterone to estrogen, SHBG binding free testosterone) and accelerators (positive drivers — IGF-1, mTOR, free T). Most people only push accelerators. Real optimization means simultaneously removing governors AND pushing accelerators. Like trying to drive a car with the parking brake on — you can floor the gas but you won’t move fast until you release the brake.

Addiction is a classic Law 1 system. The dopaminergic reward circuitry is the governor — it has been hijacked, and the person has adapted their entire physiology around the hijacked state. Withdrawal is the brake locking up. Every maintenance drug on the market — Suboxone, methadone, naltrexone — is an accelerator. They are gas. They do not release the brake. They just manage the feeling of the brake being locked up, and they tether the patient to a lifetime prescription in the process.

Ibogaine is different. Ibogaine releases the governor. A single oral dose of 10-20 mg/kg upregulates GDNF (glial cell line-derived neurotrophic factor) in the ventral tegmental area — the exact brain region where addiction’s dopaminergic pruning takes place. GDNF regenerates dopaminergic neurons. The brake itself gets physically rebuilt. In peer-reviewed literature, a single flood dose has been shown to produce durable abstinence in 50-70% of opioid-dependent participants at 8-week follow-up, a figure nothing in the SSRI or opioid-maintenance literature comes close to.

Plus: 33 known deaths from ibogaine worldwide since 1990, per the National Institute of Health. For context, fentanyl kills over 70,000 Americans every year. That’s the molecule the DOJ just prosecuted my friend for distributing.

Deep Biochemistry: What Ibogaine Actually Does

Ibogaine is a promiscuous polypharmacological molecule, and that breadth is precisely why it works where single-target drugs fail:

• Kappa-opioid receptor (κ-OR) agonist — Ki ~2-4 μM. Kappa agonism drives the oneirogenic / “review tape” experience.
• Mu-opioid receptor weak agonist/modulator — Ibogaine and its primary metabolite noribogaine occupy μ-OR without producing respiratory depression, and this neutralizes opioid withdrawal without re-creating the high.
• NMDA glutamate receptor antagonist (non-competitive, IC50 ~1-3 μM) — same pathway ketamine exploits. Links to the rapid-onset antidepressant and memory-reconsolidation windows that make ibogaine useful for trauma rewiring.
• α3β4 nicotinic acetylcholine receptor antagonist — the receptor most correlated with nicotine and stimulant reinforcement. Major component of the anti-addiction effect.
• Sigma-2 ligand (Ki ~200 nM) — implicated in neuroprotective AND cardiotoxic profile.
• SERT and 5-HT2A modulator — contributes to mood elevation and mystical-experience phenotype.
• GDNF/BDNF upregulation via noribogaine (t½ ~28-49h, vs ibogaine’s 4-7h) — the mechanism that rebuilds dopaminergic circuitry. This is the structural breakthrough.

Oral bioavailability: ~70%. Cardiac risk: hERG K+ channel blockade → QTc prolongation. Safety absolutes: cardiac screening, no co-administration with QT-prolonging drugs, no recent opioid use for ≥24 hours.

The Ameen Case: A Pattern You Need to Recognize

I am not a lawyer. I’m not going to pretend to know every procedural detail of what the DOJ is doing to my friend. But I can recognize a pattern, and this one is older than I am.

In March of 2021 a client of Ameen’s — an older bodybuilder and former wrestling champion named Andy Haman — came to him for help with alcohol dependency. Ameen was present during a session in his basement. Haman had had elbow surgery five days prior; per the coroner’s report, he was septic from a post-surgical infection his wife reportedly knew about. Haman had an enlarged heart, three times the size of normal. His arteries were compromised. In short, Haman was medically unwell in ways that had nothing to do with ibogaine.

The session went wrong. Haman died. The DOJ’s charging document paints Ameen as a dealer who killed a client. The forensic reality is considerably more complex. The full autopsy lists multiple contributing factors. The ibogaine causation has not — and cannot — be proven to the standard federal drug-delivery-resulting-in-death convictions normally require, which is why I expect that enhancement to be dropped before this reaches a jury.

But that’s not the point of this article. The point is this: if Andy Haman had walked into a hospital and received a federally approved drug that then killed him given his underlying conditions, we would call it a tragic outcome. No surgeon would go to prison. No prescriber would face 20 years. Because Ameen is a bodybuilder with no MD credential, operating in a space where no MD is legally allowed to operate because ibogaine is Schedule I, the DOJ can paint him as a street dealer. The very illegality of ibogaine creates the vacuum Ameen was trying to fill.

This is the same pattern we saw with Harry Anslinger’s cannabis prosecutions in the 1930s. The same pattern we saw with the DOJ’s 1970s war on MDMA researchers and MAPS’ founder Rick Doblin decades before the MDMA-PTSD Phase 3 results. Pioneers get prosecuted, then vindicated, and by then the pioneer has already paid the price. Pioneers aren’t wrong. They’re early. And being early in a prohibition regime means wearing the consequences so the next generation doesn’t have to.

What I’m Asking You to Do

Three things.

First, educate yourself. Read the peer-reviewed literature on ibogaine — Mash et al. 2000 on pharmacokinetics, the NIH systematic review data, the Marton et al. 2019 paper on GDNF/BDNF upregulation. Read the trip reports. Read the interviews with people whose lives this molecule saved. When your representative votes on psychedelic policy, know what you’re talking about.

Second, follow the Ameen case. If the DOJ wins a conviction here, it sets a precedent that every underground healer in this country is one indictment away from 20 years. If the DOJ loses, the door cracks open.

Third, talk about it. The loudest voices in this space are still the anti-drug establishment, even as Navy SEALs fly to Mexico for ibogaine sessions because their VA doctors can’t help them. The bipartisan science is here. The cultural acceptance is lagging because people who have benefited are afraid to say so publicly. Be one of the people who says so.

I’ll keep writing. The next article will cover the microdose protocol in more technical depth — dose curves, timing, cardiac markers, what to watch for. The one after that will probably be about the case as it develops. And if I eventually do a flood dose — again, under Ameen’s supervision — I’ll document that too.

The molecule is real. The science is real. The man who has taught me more about it than any doctor alive is sitting with a federal indictment hanging over his head, and that is an injustice the American biohacking community needs to be loud about.

FAQ

Is ibogaine legal in the United States in 2023?

No. Ibogaine is Schedule I federally — the government’s most restrictive classification, which means officially “no accepted medical use.” This designation is anti-scientific on its face given the published literature. Colorado decriminalized a short list of natural psychedelics in November 2022 but ibogaine was not included on the initial roster. A state panel is reportedly working on ibogaine-specific framework. It is legal in New Zealand, unregulated in Mexico, and operating in a grey zone in Brazil, Costa Rica, and South Africa.

What is a microdose of ibogaine and what is it for?

A microdose is 2-8 mg of ibogaine HCl, administered 1-3 times per week in cycles of 4-8 weeks. It is sub-perceptual — you do not get the oneirogenic visionary experience. The effects are subtle and cumulative: mood baseline lift, reduced cravings, emotional calibration, neuroplasticity support. It does not replace a flood dose for severe addiction cases but serves as a maintenance and optimization tool.

Why do you trust guru ameen over a licensed MD for ibogaine supervision?

Because ibogaine is not taught in medical school, and the MDs who could legally administer it in the United States don’t exist (it’s Schedule I). The practitioners with the deepest protocol knowledge are the underground researchers who have personally taken the molecule, run it on others, and systematically logged outcomes for years. Ameen has six years of direct supervision experience and a personal recovery history with this compound. That is more relevant expertise than any medical license.

Isn’t ibogaine dangerous?

It can be, if used carelessly. The cardiac risk (hERG blockade, QTc prolongation) and drug interaction profile mean cardiac screening is mandatory and stacking with QT-prolonging medications is off the table. In properly screened, properly supervised settings, the safety record is remarkable — 33 known deaths worldwide since 1990 per NIH data, almost all involving poly-drug use or undiagnosed cardiac issues. Compare to fentanyl: ~70,000+ U.S. deaths per year.

What is the current status of the Ameen Alai federal case?

Ameen was indicted in late 2022 on a single count of distribution resulting in death — a charge carrying a mandatory minimum of 20 years in federal prison. I expect the “resulting in death” enhancement to be dropped because the underlying forensic case cannot meet the sole-cause-of-death standard federal conviction requires. The broader distribution charge is a different matter. The McBride Law Firm is handling his defense.

Next Time

I’m going to write a much more technical piece on the microdose protocol itself — specific dosing, titration schedule, the cardiac markers you should be tracking, what Ameen has taught me about individual variability in response. If you’re a biohacker with a serious interest in this compound, that’s the one to read.

And if you’re in a position to help the Ameen defense fund — or even just to share the story with someone who hasn’t heard it — do it. The man who taught me this molecule is fighting a federal case that will determine whether any American is allowed to help another American reset their neurochemistry outside the pharmaceutical pipeline. I don’t take that lightly. Neither should you.

More soon.

— tony huge